...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cardiovascular electrophysiology >Effect of ICD implantation on cardiovascular outcomes in patients with cardiac amyloidosis: A systematic review and meta-anaylsis
【24h】

Effect of ICD implantation on cardiovascular outcomes in patients with cardiac amyloidosis: A systematic review and meta-anaylsis

机译：ICD植入对心肌淀粉样症患者心血管结果的影响：系统评价和荟萃缺陷

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction Cardiac amyloidosis is associated with a high rate of sudden cardiac death (SCD). Whether implantable cardioverter-defibrillator (ICD) use in such patients prevents SCD is uncertain. This study assesses outcomes of ICD use in patients with cardiac amyloidosis. Methods A systematic review and meta-analysis of data were performed after searching multiple databases and scientific sites pertaining to ICD use and cardiac amyloidosis. Of 8260 citations identified, six studies comprising 194 patients met inclusion criteria. Results Mean values and frequencies of patient characteristics were as follows: mean NT-proBNP: 6867.9 pg/mL, mean left ventricular ejection fraction: 48.1%, heart failure: 67%, nonsustained ventricular tachycardia: 51%, syncope: 21%, and secondary prevention: 33%. During the mean follow-up period of 18.21 months, 18% of patients received appropriate ICD treatment and 5% received inappropriate ICD treatment. The mortality rate was 31%. Two studies assessed the difference between patients with appropriate ICD treatment and patients with absence of appropriate ICD treatment. There was no difference between the two groups when stratified on multiple selected third variables except for two subgroups. Male gender was associated with a higher rate of appropriate ICD treatment, whereas New York Heart Association class III or IV heart failure patients was associated with a lower rate of appropriate ICD treatment. Conclusion The frequency of appropriate ICD treatment in cardiac amyloidosis is low and is not predicted by nonsustained ventricular tachycardia. Male gender is associated with appropriate ICD treatment. New York Heart Association class III or IV heart failure is associated with lower rate of appropriate ICD treatment.
机译：引言心脏淀粉样蛋白病与突然的心脏死亡率（SCD）有关。可植入的心脏除颤器（ICD）在这些患者中使用是否可防止SCD不确定。本研究评估了心脏淀粉样蛋白患者的ICD使用的结果。方法在搜索与ICD使用和心脏淀粉样症有关的多个数据库和科学遗址之后进行系统审查和数据分析。鉴定了8260个引文，六项研究包括194名患者符合纳入标准。结果患者特征的平均值和频率如下：平均NT-PROPNP：6867.9 pg / ml，平均左心室喷射部分：48.1％，心力衰竭：67％，非静态心室性心动过速：51％，晕厥：21％，和二级预防：33％。在18.21个月的平均随访期间，18％的患者接受适当的ICD治疗，5％接受不适当的ICD治疗。死亡率为31％。两项研究评估了适当ICD治疗患者的患者的差异，患者没有适当的ICD治疗。除了两个子组之外，两组在多个选定的第三变量上没有区别。除了两个子组。男性性别与适当的ICD治疗率较高，而纽约心脏协会III类或IV心力衰竭患者与适当的ICD治疗率较低相关。结论心脏淀粉样源性病的适当ICD治疗的频率低，不受耐受性心室性心动过速预测的。男性性别与适当的ICD治疗有关。纽约心脏协会III类或IV心力衰竭与适当的ICD治疗率较低有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号